Literature DB >> 32783115

ARCHITECT® urine-neutrophil gelatinase-associated lipocalin (u-NGAL) assay as new prognostic marker for clear cell Renal Cell Carcinoma (ccRCC) (preliminary results).

Hajer Ben Khadhra1, Françoise Rose-Robert2, Yves Edouard Herpe3, Henri Sevestre4, Gabriel Choukroun5, Luc Catherine6, Carole Amant7, Fabien Saint8,9,10.   

Abstract

INTRODUCTION: Biomarkers for the diagnosis and monitoring treatment response of kidney cancer are urgently needed. Neutrophil gelatinase-associated lipocalin (NGAL) is a relevant urinary biomarker for the diagnosis of a wide variety of acute and chronic kidney diseases. Its potential utility as a prognostic marker of kidney cancer is largely unknown and, therefore, was the subject of this investigation.
MATERIALS AND METHODS: A retrospective study was done on 50 kidney tumor patients (urine samples prospectively collected before nephrectomy between 2004 and 2012, stored at Biobank Resource Center). The specificity, sensitivity and the predictive value of NGAL were determined for progression-free and disease-specific survival after nephrectomy in renal cell carcinoma (particularly, the clear cell renal cell carcinoma (ccRCC)). Urinary NGAL concentration (u-NGAL) was determined by CMIA technique (ARCHITECT® urine NGAL essay/ABBOTT®).
RESULTS: Out of the 50 kidney tumor patients, 40 had clear cell carcinoma with a median u-NGAL excretion of 1.4 (IQR: 5.76) ng/mg urinary creatinine (Ucr). u-NGAL was correlated to tumor stage (p = 0.005), and Fuhrman grade (p = 0.0002). Multivariate Cox regression analysis showed a significant association between u-NGAL excretion and clear cell renal cell carcinoma progression free survival and disease specific survival (p = 0.002; p = 0.0001).
CONCLUSIONS: Urinary NGAL was significantly associated with the stage and the grade of kidney cancer. u-NGAL excretion could be considered as a potential biomarker to identify ccRCC patients with the more pejorative outcomes.

Entities:  

Keywords:  Clear cell renal carcinoma; NGAL; Urinary markers

Mesh:

Substances:

Year:  2020        PMID: 32783115     DOI: 10.1007/s11255-020-02604-w

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  22 in total

Review 1.  Clinical practice. Small renal mass.

Authors:  Inderbir S Gill; Monish Aron; Debra A Gervais; Michael A S Jewett
Journal:  N Engl J Med       Date:  2010-02-18       Impact factor: 91.245

Review 2.  Renal-cell carcinoma.

Authors:  Herbert T Cohen; Francis J McGovern
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

3.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

4.  [The neutrophil gelatinase-associated lipocalin, or LCN 2, marker of aggressiveness in clear cell renal cell carcinoma].

Authors:  C Perrin; J-J Patard; F Jouan; N Collet; S Théoleyre; J Edeline; S Zerrouki; B Laguerre; M-A Bellaud-Roturaud; N Rioux-Leclercq; C Vigneau
Journal:  Prog Urol       Date:  2011-09-03       Impact factor: 0.915

5.  Sensitivity and specificity of urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 for the diagnosis of renal cell carcinoma.

Authors:  Jeremiah J Morrissey; Amy N London; Matthew C Lambert; Evan D Kharasch
Journal:  Am J Nephrol       Date:  2011-09-07       Impact factor: 3.754

6.  Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression.

Authors:  A Friedl; S P Stoesz; P Buckley; M N Gould
Journal:  Histochem J       Date:  1999-07

Review 7.  The Heidelberg classification of renal cell tumours.

Authors:  G Kovacs; M Akhtar; B J Beckwith; P Bugert; C S Cooper; B Delahunt; J N Eble; S Fleming; B Ljungberg; L J Medeiros; H Moch; V E Reuter; E Ritz; G Roos; D Schmidt; J R Srigley; S Störkel; E van den Berg; B Zbar
Journal:  J Pathol       Date:  1997-10       Impact factor: 7.996

Review 8.  Neutrophil gelatinase-associated lipocalin in cancer.

Authors:  Giuseppe Lippi; Tiziana Meschi; Antonio Nouvenne; Camilla Mattiuzzi; Loris Borghi
Journal:  Adv Clin Chem       Date:  2014       Impact factor: 5.394

9.  Cancer statistics, 2008.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Taylor Murray; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2008-02-20       Impact factor: 508.702

10.  Prognostic significance of morphologic parameters in renal cell carcinoma.

Authors:  S A Fuhrman; L C Lasky; C Limas
Journal:  Am J Surg Pathol       Date:  1982-10       Impact factor: 6.394

View more
  1 in total

Review 1.  Kidney Cancer and Chronic Kidney Disease: Too Close for Comfort.

Authors:  Pedro Caetano Pinto; Cindy Rönnau; Martin Burchardt; Ingmar Wolff
Journal:  Biomedicines       Date:  2021-11-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.